Nonalcoholic Fatty Liver Disease PBMC
Nonalcoholic Fatty Liver Disease PBMC - Cryopreserved PBMCs in CryoStor CS10 from IRB-consented donors with clinically confirmed NAFLD/MASLD. Ideal for metabolic inflammation research: monocyte and macrophage models, immunometabolism assays, lipotoxicity studies, and single-cell transcriptomics. Stratification by disease stage, fibrosis, and diabetes status.
Nonalcoholic Fatty Liver Disease PBMC for Metabolic Inflammation Research
Nonalcoholic Fatty Liver Disease PBMC products are sourced from IRB-consented donors clinically diagnosed with nonalcoholic fatty liver disease (NAFLD, also described as MASLD) and processed within 24 hours of collection under standardized SOPs. These cryopreserved peripheral blood mononuclear cells are stored in CryoStor® CS10 and shipped on dry ice. Research Use Only (RUO).
Metabolic Inflammation and Why PBMC
- NAFLD is a metabolic, not autoimmune, liver disease. It begins with hepatic steatosis, the accumulation of triglyceride in hepatocytes, in the absence of significant alcohol intake.
- The dominant drivers are insulin resistance, obesity, and excess free fatty acid flux to the liver, together with increased de novo lipogenesis. NAFLD is closely linked to type 2 diabetes, dyslipidemia, and the broader cardiometabolic phenotype.
- Lipotoxicity from specific lipid species, rather than neutral triglyceride itself, causes hepatocyte stress and injury, and this is what distinguishes progressive steatohepatitis from bland steatosis.
- Progression to nonalcoholic steatohepatitis involves hepatocyte ballooning, lobular inflammation, and fibrosis, with recruitment of circulating monocytes that differentiate into monocyte-derived hepatic macrophages alongside resident Kupffer cells.
- Because these liver macrophages originate in the peripheral blood monocyte pool, PBMCs provide a directly relevant, accessible source of the innate cells implicated in disease progression, as well as lymphocyte populations altered in metabolic disease.
- PBMCs support live-cell immunophenotyping, monocyte and macrophage differentiation models, lipid loading experiments, immunometabolic assays, and single-cell transcriptomics that acellular matrices cannot.
Donor Stratification Available
- Disease stage: simple steatosis versus nonalcoholic steatohepatitis where documented
- Fibrosis stage or non-invasive fibrosis score where available
- Biopsy-confirmed versus imaging or clinically diagnosed donors
- Type 2 diabetes and insulin resistance status
- BMI category and dyslipidemia status
- Treatment status, including GLP-1 receptor agonist, insulin sensitizer, or lifestyle management only
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed NAFLD donors
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- Custom aliquots available; shipped on dry ice
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified NAFLD diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- BMI, metabolic comorbidities, and liver enzyme values where available
- Additional NAFLD-specific data available upon request
Applications
- Monocyte subset immunophenotyping and monocyte-derived macrophage differentiation models
- Immunometabolism assays, including mitochondrial and glycolytic function
- Lipid loading and lipotoxicity models in primary human cells
- Ex vivo stimulation and inflammatory cytokine release profiling
- Bulk and single-cell transcriptomic analysis of metabolic inflammation
- Target validation and mechanism-of-action work for NASH and metabolic therapeutics
- Peripheral immune correlate discovery for fibrosis progression
- Drug screening in disease-state primary cells
Other Nonalcoholic Fatty Liver Disease Specimen Types
- Nonalcoholic Fatty Liver Disease Plasma
- Nonalcoholic Fatty Liver Disease Serum
- Nonalcoholic Fatty Liver Disease Whole Blood
- Nonalcoholic Fatty Liver Disease Leukopak
- Nonalcoholic Fatty Liver Disease Bulk Plasma
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Nonalcoholic Fatty Liver Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse all donor cohorts and current stock, visit our human PBMCs page.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.